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Comprehensive prenatal care has be­
come the hallmark of modern obstetrical prac­
tice. Awareness by both physicians and pa­
tients that such care is necessary for 
satisfactory perinatal outcome has led to the es­
tablishment of an obstetrical subspecialty, Ma­
ternal Fetal Medicine, to provide a higher level 
of prenatal care and to increase our knowledge 
of perinatal events. Many of the management 
techniques currently being used for high-risk 
pregnancies can be readily applied to the rou­
tine obstetrical population. The additional physi­
cian time and laboratory tests required are mini­
mal, and the early identification and prevention 
of perinatal complications will eliminate the 
need for "crisis" medicine. 
Identification of the High-Risk Patient 
The first step toward initiating a manage­
ment plan for a high-risk pregnancy is recogni­
tion that a poor perinatal outcome is possible. 
Early identification of the "at-risk" fetus begins 
with the first antenatal screening visit. Although 
most conditions associated with an adverse ma­
ternal or fetal outcome have long been recog­
nized, I have found it helpful to use a risk-scor­
ing approach that provides a semiquantitative 
risk estimate. 1· 2 This method takes into consid­
eration various historical, physical, and labora­
tory data to generate a numerical risk score; in 
general, as the risk score increases, the likeli­
hood of an unfavorable perinatal outcome also 
increases. Depending on the clinical setting, 
one quarter to one third of all pregnancies will 
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be identified prospectively as high risk and can 
be expected to experience the majority of peri­
natal mortality and morbidity. It is in this group 
of high-risk patients that recently developed 
methods of fetal surveillance are likely to find 
their greatest value. While details of this risk­
scoring system are beyond the scope of this 
discussion, it should be mentioned that the Vir­
ginia State Department of Health currently has 
plans to implement a risk-scoring system into 
the state health care system. 
Dr. Robert Petr es has previously ad­
dressed the problem of identification of the 
high-risk gravida. Although his classification of 
pregnancies into various risk categories based 
on the worst single antepartum complication is 
a different approach from the numerical risk­
scoring system, he accomplishes much the 
same result-prospective identification of the 
patient at risk for an adverse perinatal outcome. 
Management 
Ideally, every woman should be seen by 
an obstetrician prior to conception. At this time 
the physician may identify medical problems 
that should receive attention. The patient should 
be made aware of the importance of early pre­
natal care and be encouraged to seek an early 
diagnosis of pregnancy. The patient-physician 
relationship established at the preconception 
visit will encourage this. 
Office management of the high-risk grav­
ida begins with the initial visit. Postconception, 
patients should be seen as soon as possible in 
the office. It is difficult to convince patients of the 
importance of prenatal care if they must wait 3 
to 4 weeks for their first postconception visit. If 
the physician is not readily available, the initial 
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office screening should be performed by a 
nurse. The patient's blood pressure and urine 
should be checked, a pregnancy test performed 
to confirm pregnancy, and a check list history 
taken to identify any significant problems that 
may require immediate attention by the physi­
cian. If the patient is entirely normal with a neg­
ative history, she may be scheduled to see the 
physician at a later date; however, if a problem 
is identified on the screening visit, it should be 
dealt with as soon as possible. 
Initial Visit 
The objectives of the initial visit are to de­
termine the health of the mother and fetus, to 
determine the gestational age of the fetus, and 
to initiate a plan for continuing obstetrical care. 
A thorough physical should be performed and a 
complete history taken. Special attention should 
be given to a chronological listing of all previous 
pregnancies and include length of gestation, 
fetal weight, route of delivery, and any maternal 
or fetal complications Past obstetrical perform­
ance is the single most important historical fact 
that may predict potential problems during the 
current pregnancy The date and character of 
the last two menstrual periods should be in­
cluded at this time. Particular attention should 
be given to the funduscopic exam, thyroid, 
heart, lungs, breasts, fundal height, and to the 
presence or absence of fetal heart tones. 
Routine laboratory work which should be 
performed on all pregnant patients is listed be­
low: 
1 CBC 
2. Urine culture 
3. Urinalysis 
4 VDRL 
5. Blood type and Rh titers 
6. Atypical blood group antibodies 
7. Pap smear 
8. Gonococcal culture 
9. Rubella titers 
10. Two-hour postprandial blood sugar 
Additional laboratory work may be needed in 
selected cases depending on the patient's his­
tory and physical findings. The more common 
additional studies to evaluate patients with hy­
pertension or chronic renal disease include a 
SMA 12, SMA 6, and a 24-hour urine collection 
for protein and creatinine clearance. Diabetic 
patients will need blood sugar determinations 
and an ophthalmology consultation in addition 
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to the tests for renal evaluation. Supplemental 
tests such as thyroid function tests, parathyroi<;l 
function tests, and liver function tests should be 
obtained on those patients where historical @r 
physical data suggest possible problems. The 
CBC, urine culture, and the two-hour posh 
prandial blood sugar should be repeated at 32 
weeks gestation because of the complications 
associated with undiagnosed anemia, pyelone­
phritis, and diabetes in the third trimester. In 
routine uncomplicated pregnancies no addi-· 
tional laboratory tests need be repeated. Atypi­
cal antibodies may develop in patients who be­
come sensit ized to various blood group 
antigens and many of these atypical antibodies; 
can cause erythroblastosis and intrauterine fetal: 
death. These patients need to be treated in a; 
fashion similar to an Rh negative sensitized pa­
tient. The blood bank should provide informa­
tion concerning which of the atypical antibodies 
are possible causes of erythroblastosis. Rubella 
titers should be included in all pregnant women; 
patients with positive rubella titers can be reas­
sured that rubella will not be a problem during 
the course of pregnancy Patients with negative 
rubella titers may be vaccinated in the post­
partum period If the two-hour postprandial 
blood sugar is greater than 120 mg/%, a glu­
cose tolerance test (GTT) should be performed 
to rule out gestational diabetes. Since the de­
mand for insulin increases with gestation a sec­
ond two-hour postprandial blood sugar or GTT 
should be performed at 32 weeks. 
The frequency of subsequent office visits 
must be determined according to the needs of 
the patient as should the need for additional lab­
oratory work and possible antenatal hospital­
ization. 
Regardless of the patient's high risk 
classification the objectives of prenatal manage­
ment remain the same and include evaluation of 
the maternal condition, fetal condition, and ges­
tational age These must be considered on 
each prenatal visit. Although the number of ad­
ditional visits, consultations and laboratory work 
necessary for proper evaluation should be indi­
vidualized there are certain management tech­
niques that apply to all patients in the first, sec­
ond and third trimesters of pregnancy 
First Trimester 
Maternal condition should be evaluated 
with a history and physical examination, routine 
laboratory work, and selected laboratory work 
and procedures. when indicated, to establish a 
baseline medical status during the first trimes­
ter. 
Fetal condition is difficult to assess in the 
first trimester and very little can be done to alter 
the course of pregnancy at this stage of gesta­
tion. Progressive fundal growth should be rou­
tinely documented as a means of assessing 
fetal condition. If uterine growth is abnormal or 
vaginal bleeding should ensue, ultrasonic evi­
dence of a normal or abnormal gestation sac or 
fetus will provide prognostic data; this may lead 
to earlier intervention in cases of obvious preg­
nancy loss. 
Gestational age must be accurately as­
sessed during the first and second trimesters of 
pregnancy. The difficulty in accurately assess­
ing gestational age in the third trimester is well 
known. The date, duration and character of the 
last menstrual period (LMP) should be clearly re­
corded in the chart. Additional information re­
garding the regularity of the patient's menstrual 
cycle and her most recent means of birth con­
trol should be documented. Uterine size during 
the first trimester of pregnancy is also useful in 
determining gestational age. 
Second Trimester 
Maternal condition should be evaluated 
routinely with blood pressure determination, 
maternal weight gain, and urinalysis for protein, 
glucose and acetone. The frequency of visits 
and the need for additional lab work and pos­
sible hospitalization must be determined at this 
time. The minimum interval between office visits 
for patients with otherwise uncomplicated preg­
nancies should be every four weeks. 
Although very little can be done to alter 
the course of pregnancy at this stage in gesta­
tion, fetal condition can still be evaluated by 
monitoring progressive fundal growth and the 
development of fetal movement. Should prob­
lems arise, many of the more serious fetal con­
ditions can be evaluated with a careful ul­
trasound examination. 
The second trimester of pregnancy con­
tains many gestational landmarks that are im­
portant in determining gestational age for future 
management. The appearance of the first fetal 
heart tones heard with an unamplified fetoscope 
is a reliable means of determining gestational 
age; these should be heard at 20 weeks, plus 
or minus 1 week, in the majority of pregnancies. 
From 1 7 weeks on patients should be seen 
weekly until fetal heart tones have been heard 
with the unamplified fetoscope In addition, a 
patient should also be asked to mark the date 
when she first feels fetal movement. If towards 
the end of pregnancy fetal movement has been 
present for more than 22 weeks and fetal heart 
tones have been present for 20 weeks, the pa­
tient has a 95% chance of being at least 39 to 
40 weeks pregnant. Fundal height should be re­
corded as accurately as possible in the second 
trimester of pregnancy because of the narrow 
range of standard deviation in uterine size that 
occurs at this time. The large difference in uter­
ine sizes that occurs with infants who are small, 
average or large for their gestational age does 
not usually occur until the third trimester of 
pregnancy. If fetal gestational age can not be 
reliably determined, an ultrasound study for 
.biparietal diameter should be obtained. 
Third Trimester 
The mother and fetus both require in­
creased surveillance during this period of gesta­
tion as numerous complications may arise in 
previously normal pregnancies Early recogni­
tion and proper intervention will decrease the 
perinatal morbidity and mortality associated 
with many of these developing problems 
Maternal condition should be evaluated 
every two weeks during the third trimester and 
every week during the last month. Closer obser­
vation may be required in selected patients. 
Maternal condition should be evaluated with 
routine blood pressure, urinalysis, and weight 
gain observation. Routine laboratory work 
which should be repeated early in the third tri­
mester of pregnancy includes a CBC, a two­
hour postprandial blood sugar, and a urine cul­
ture. More frequent evaluation of renal function 
tests, blood sugars and additional laboratory 
work will be necessary in selected patients. 
Evaluation of fetal condition during the 
third trimester of pregnancy has become a ma­
jor part of antepartum fetal management. Both 
biophysical and biochemical means of fetal 
monitoring are available. At the present time, 
the only useful biochemical test for evaluating 
fetal well-being is urinary or serum estriols. 
However, if estriols are to be used to predict 
fetal compromise, specimens must be collected 
daily and the results must be available to the 
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physician within 1 2 hours. An isolated or weekly 
estriol value should not be used to monitor fetal 
well-being in complicated pregnancies. 
The biophysical tests of fetal well-being in­
clude nonstressed fetal heart rate monitoring 
(NST) and an oxytocin challenge test (OCT). 3 
The decision as to when to start antenatal fetal 
heart rate monitoring should be based on the in­
dividual patient and the clinical situation. Mon­
itoring may be indicated as early as 26 to 28 
weeks of gestation in patients with advanced 
hypertension or diabetes, or delayed until 42 
weeks in a previously uncomplicated post-term 
pregnancy. In general, antepartum fetal heart 
rate monitoring should not be performed prior to 
the time in gestation when the physician would 
consider terminating a pregnancy because of 
fetal indications. There are limited data avail­
able on the use of antepartum monitoring prior 
to 30 weeks of gestation. 
Indications for antepartum fetal heart rate 
monitoring are any pregnancy at risk for uter­
oplacental insufficiency. There are no con­
traindications to the NST. The oxytocin chal­
lenge test is associated with the following 
contraindications: ruptured membranes, sus­
pected abruptio placenta, undiagnosed uterine 
bleeding, placenta previa, previous cesarean 
section, incompetent cervix, previous pre­
mature labor and polyhydramnios. In addition, 
the OCT has not been shown to be of value in 
the management of erythroblastosis fetalis. In 
general, negative OCT or reactive NST allows 
the clinician to avoid unnecessary premature in­
tervention and has a false-positive rate (fetal 
death in 1 week of monitoring) of 2 to 5 per 
1 000 A nonreactive NST or a positive OCT 
alerts the physician to possible fetal com­
promise and may be an indication for inter­
vention before fetal death or irreversible dam­
age occurs. 
The NST has been shown to be as reliable 
as the OCT. Because of the reliability and sim­
plicity of the NST, this monitoring technique has 
become the primary means of antenatal fetal 
monitoring here at the Medical College of Vir­
ginia. An outline of procedure for patient care is 
listed below. 
1. The "at-risk" patient is identified us­
ing clinical risk assessment and scor­
ing techniques at the first antenatal 
visit and as problems develop during 
gestation. 
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2 Based on the clinical situation the 
NST may be started as early as 28 
weeks. 
3 The patient is followed with weekly 
NSTs, as long as she remains reac­
tive. 
4. Any inadequate NST is repeated 
within 24 hours. Any nonreactive 
NST is evaluated the same day with 
an oxytocin challenge test. 
o If the OCT is negative, the patient is 
scheduled to have a NST the next 
week. 
6. A suspicious, hyperstimulation, or 
unsatisfactory OCT is repeated 
within 24 hours. 
7. Urinary or serum estriols may be ob­
tained for additional information, de­
pending on the clinical situation, and 
must be collected daily to be useful. 
8. If a nonreactive NST is followed by a 
positive OCT, serious consideration 
must be given to delivering the fetus. 
At this time, amniocentesis may be 
performed and if the amniotic fluid 
indicates fetal maturity, or meco­
nium-stained fluid is found, the fetus 
should be delivered. 
9. If the amniotic fluid is clear and there 
is evidence of fetal pulmonary im­
maturity, a decision is made based 
on which risk is greater, prematurity 
or the in utero environment. 
1 0 In the face of low or falling estriols, 
with a nonreactive NST and/or a 
positive OCT, we at MCV recom­
mend delivering the fetus if it is vi­
able. 
11 . If the estriols are stable and in the 
normal range, with a nonreactive 
NST or a positive OCT. the situation 
is ambiguous. A decision to await 
further maturation or to deliver the 
patient may be appropriate. Clinical 
judgment based on the overall as­
sessment of the maternal status, 
pregnancy duration. and the condi­
tion of the fetus is required. 
Determination of gestational age in the 
third trimester of pregnancy is indeed difficult. 
Ultrasound provides information about fetal size 
but does not differentiate between the small 
premature infant and the standard gestational 
age term infant. To predict gestational age re­
liably, information from the first and second tri­
mesters must be available. During the third 
trimester of pregnancy the emphasis shifts from 
gestational age to determination of fetal matu­
rity Without adequate clinical data concerning 
gestational age or when premature interruption 
of pregnancy is being considered prior to 39 
weeks, I advocate amniocentesis for a lecithin­
sphingomyelin (L/S) ratio. 
Summary 
Recognition of those patients at risk for a 
poor perinatal outcome is the most important 
step in reducing perinatal morbidity and mortal­
ity. Once at-risk patients are recognized, in­
tensive observation with frequent assessments 
of maternal condition, fetal condition, and ges­
tational age can be accomplished with minimal 
additional physician time and laboratory tests. 
The decision of when or when not to intervene 
in a pregnancy is not an easy one and should 
be based on all available data, an important 
part of which is information collected during the 
first and second trimester of pregnancy Re­
gional perinatal consultation services should be 
used more frequently for patients with manage­
ment problems. Developing problems should be 
treated aggressively with antepartum hospital­
ization, intensive observation and evaluation, 
and consultation. Proper assessment of mater­
nal condition, fetal condition, and gestational 
age will prevent many of the more serious com­
plications and may allow the patient to remain in 
her own community under the direct care of her 
local physician. If, however, the patient requires 
a level of care that cannot be provided in her 
own community, she should be transferred to a 
regional perinatal center without hesitation. 
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